Johnson & Johnson (NYSE: JNJ)-owned Janssen Pharmaceuticals Inc. has acquired biopharmaceutical business Xo1 Ltd. for an undisclosed amount.

Xo1, headquartered in Cambridge, England, is working to develop an anti-clotting drug that could be used to treat thrombosis, which causes blood clots in leg veins. The company raised $11 million from venture capital firm Index Ventures in 2013.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.